Dare Bioscience Q2 10-Q: Going Concern Doubt, Nasdaq Delisting Hearing Set for Late August

summarizeSummary

Dare Bioscience disclosed going concern doubt, a Nasdaq delisting hearing in late August, and FDA concerns about its Ovaprene trial design in its Q2 2026 10-Q.

check_boxKey Events · Earnings and Guidance · DARE

• Going Concern Doubt

  Management states substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date, citing uncertain revenue timing and the need for additional capital.

• Cash Position and Working Capital Deficit

  Cash and cash equivalents of $12.6 million as of June 30, 2026, all of which represented grant funds restricted to specific projects. Working capital deficit of approximately $0.2 million.

• Nasdaq Delisting Hearing

  Hearing before the Nasdaq Hearing Panel scheduled for late August 2026 to address stockholders' equity deficiency. Delisting would substantially impair capital raising and trading liquidity.

• FDA Ovaprene Protocol Caution

  FDA approved the protocol amendment to remove the 250-completer expectation but cautioned the modified study may not generate sufficient safety evidence to support a favorable premarket approval decision.

auto_awesomeAnalysis · DARE · Life Sciences

Dare Bioscience's Q2 2026 10-Q reveals substantial doubt about its ability to continue as a going concern within 12 months. Cash of $12.6 million is entirely restricted to grant-funded projects, leaving a working capital deficit of $0.2 million. The company faces a Nasdaq delisting hearing in late August 2026 after stockholders' equity fell below $2.5 million. The FDA approved an Ovaprene protocol amendment but cautioned it may not generate sufficient safety evidence for approval. These combined risks threaten the company's listing and its ability to fund operations.